Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review
- 18 September 2007
- journal article
- review article
- Published by Wiley in Transfusion
- Vol. 47 (10), 1919-1929
- https://doi.org/10.1111/j.1537-2995.2007.01416.x
Abstract
Patients with thalassemia major require iron chelation therapy (ICT) to prevent complications from transfusional iron overload. Deferoxamine is effective, but requires administration as a slow continuous subcutaneous or intravenous infusion five to seven times per week. Deferiprone is a three-times-daily oral iron chelator, but has limited availability in the United States. Deferasirox is a once-daily oral iron chelator that was approved in the United States in 2005 for patients older than 2 years of age with transfusional iron overload. Published evidence on rates of compliance with ICT and the association between compliance, and the incidence and costs of complications of iron overload, in patients with thalassemia major was reviewed. A total of 18 studies were identified reporting data on compliance with ICT, including 7 that examined deferoxamine only, 6 that examined deferiprone only, and 5 that compared deferoxamine and deferiprone; no studies reporting compliance with deferasirox were identified. In studies of deferoxamine only, estimated mean compliance ranged from 59 to 78 percent. Studies of deferiprone generally reported better compliance, ranging from 79 to 98 percent. Results of comparative studies of deferoxamine and deferiprone suggest that compliance may be better with oral therapy. Numerous studies demonstrate that that poor compliance with ICT results in increased risk of cardiac disease and endocrinopathies, as well as lower survival. Although data on the costs of noncompliance are limited, a recent model-based study estimated the lifetime costs of inadequate compliance with deferoxamine to be $33,142. Inadequate compliance with ICT in thalassemia major is common and results in substantial morbidity and mortality, as well as increased costs.Keywords
This publication has 39 references indexed in Scilit:
- Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia PatientsPharmacoEconomics, 2007
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Complications of β-thalassemia major in North AmericaBlood, 2004
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron ChelatorThe Journal of Clinical Pharmacology, 1994
- The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture systemBritish Journal of Haematology, 1994
- Prevention of heart disease by subcutaneous desferoxamine in patients with thalassaemia majorAustralian and New Zealand Journal of Medicine, 1993
- Prolonged survival in patients with beta-thalassemia major treated with deferoxamineThe Journal of Pediatrics, 1991
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985